Rhenium (Re-186) obisbemeda{Re-186-Nanoliposome (186RNL)} in Leptomeningeal Metastases [LM] Phase 1/2a Dose Escalation Trial: Initial Safety and Feasibility (SNO 2023) - Nov 11, 2023 - Abstract #CTNI-06; Pres time: Nov 17, 2023; 07:30 PM - 09:30 PM; Location: Exhibit Hall A/B; "Adjuvant MHT may induce tumor radio-sensitization, immune cell recruitment, and survival benefit when combined with CRT. Optimization of the combination therapy treatment scheme is required."
Clinical • P1/2 data • Oncology
|
|
Andrew J. Brenner; Michael Youssef; Priya U. Kumthekar; Joel Michalek; Marc Hedrick; Ande Bao; William T. Phillips; Toral R. Patel; Jeffrey S. Weinberg; John Floyd; Norman LaFrance
|